Sangamo Biosciences (SGMO) has disclosed a new risk, in the Manufacturing category. Sangamo Biosciences does not face any business risks ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of $10.00. Patrick Trucchio’s rating is based on Sangamo ...

Prior to Lyell, Ms. Turner held variety of roles in legal, operational, and portfolio strategy at Sangamo Therapeutics, Atara ...

RBC Capital Mkts has recently reduced Sangamo Therapeutics Inc (SGMO) stock to Sector Perform rating, as announced on November 3, 2023, according to Finviz. Earlier, on April 28, 2023, BofA Securities ...

Alexander Macrae; President, Chief Executive Officer, Director; Sangamo Therapeutics Inc Nathalie Dubois- Stringfellow; Senior Vice President, Chief Development Officer; Sangamo Therapeutics Inc ...

Marquez happened to be secretly videotaping the ask over lunch at the now-defunct Sangamo Club in Springfield, a hangout for ...

Sangamo Therapeutics Inc (NASDAQ:SGMO) has transformed from a Phase 1/2 company to a pre-BLA company due to significant ...

Sangamo Therapeutics (SGMO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.34 per share a year ago.

RICHMOND, Calif. (AP) — RICHMOND, Calif. (AP) — Sangamo Therapeutics Inc. (SGMO) on Tuesday reported third-quarter earnings of $10.7 million. On a per-share basis, the Richmond, California-based ...

One other stock from the same industry, Sangamo Therapeutics (SGMO), is yet to report results for the quarter ended September 2024. The results are expected to be released on November 12. This drug ...

Sangamo Therapeutics SGMO is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...